CT
Citius Oncology, Inc.
CTOR · NASDAQ
$1.14 +10.68% (+$0.11)
1M +53.27%
Market Cap $94.8M
P/E Ratio -
Div. Yield -
ROE 102.98%
Piotroski F-Score Weak
3/9Valuation
40 /100
Fair P/S 13.35x
P/B 2.35x
P/E N/A
Growth
65 /100
Stable Book val. growth 7.35%
EPS growth N/A
FCF growth N/A
Profitability
20 /100
Weak Gross margin 53.13%
FCF margin 277.34%
Net margin 648.32%
Quality
1 /100
Poor ROIC 89.09%
Asset turnover 0.06x
ROE 102.98%
Debt
51 /100
Moderate Debt/Equity 0.25x
Int. coverage -82.99x
Current ratio 0.73x
Stability
7 /100
Unstable Beta 3.53x
Profitable years 0
EPS volatility 69.16%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about CTOR
Online
Sector
Healthcare
Industry
Medical - Pharmaceuticals
CEO
Leonard L. Mazur
Employees
285
Headquarters
Cranford
Upcoming events
17 DEC
Earnings
Upcoming earnings report